TAFASITAMAB
Tafasitamab 200 mg injection, 1 vial
TAFASITAMAB (15496N)
15496N
Manner of administration:Injection
Restriction
Indication: Relapsed or refractory follicular lymphoma
Treatment phase: Continuing treatment (Cycles 6 - 12 inclusive)
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1400 mg | # of repeats: 13 | DPMA: $8,514.84 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| MINJUVI
(Tafasitamab 200 mg injection, 1 vial)
|
||||